Impact of COVID-19 on Human Adenovirus Reporting in the US
Author Information
Author(s): Abdirizak Fatima MPH, Winn Amber K. MPH, Parikh Rishika MPH, Scobie Heather M. PhD, Lu Xiaoyan MS, Vega Everardo PhD, Almendares Olivia MSPH, Kirking Hannah L. MD, Rose Erica Billig PhD, Silk Benjamin J. PhD
Primary Institution: Centers for Disease Control and Prevention
Conclusion
Reporting of human adenovirus types decreased during and after the COVID-19 pandemic, despite ongoing circulation of the virus.
Supporting Evidence
- During 2017–2023, six HAdV types accounted for 88.3% of typed specimens.
- Reporting to NATRS decreased during and after the COVID-19 pandemic.
- An increase in type 41 reporting was associated with a hepatitis cluster during 2021–2022.
- Respiratory specimens accounted for 82.3% of all specimens reported.
- 17% of specimens were identified as outbreak-related.
Takeaway
This study looked at how many cases of a virus called adenovirus were reported in the US from 2017 to 2023, especially during the COVID-19 pandemic, and found that fewer cases were reported even though the virus was still around.
Methodology
The study analyzed data from the National Adenovirus Type Reporting System (NATRS) which included voluntary reports from laboratories on adenovirus typing results.
Potential Biases
HAdV typing is differentially performed on specimens from severe infections and outbreaks, which may skew the data.
Limitations
The data may not be geographically representative due to limited laboratory participation and missing data on typing or collection dates.
Participant Demographics
Specimens were most frequently collected from infants and young children aged 0–4 years, followed by young adults aged 18–29 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website